Use of Cannabinoids for Spasticity and Pain Management in MS

被引：0
作者：
Hardeep Chohan
Ariele L. Greenfield
Vijayshree Yadav
Jennifer Graves
机构：
[1] University of California,Department of Neurology
[2] San Francisco,Department of Neurology
[3] Oregon Health and Science University,undefined
来源：
Current Treatment Options in Neurology | 2016年 / 18卷
关键词：
Multiple sclerosis; Cannabinoids; Spasticity; Pain; Tetrahydrocannabinol; Cannabidiol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Several randomized trials have demonstrated potential benefit of cannabis derivatives in the symptomatic treatment of multiple sclerosis (MS) patients. These provide class 1 and 2 evidence for cannabinoid product use for spasticity and pain in these patients. The precise best ratio or doses are not yet clear. The safety and potential long-term effects of these products on cognitive function in people with MS have not been evaluated. Since short-term memory and processing speed can be significantly impaired in many people with MS, the concern of potential cognitive impairment related to cannabis products needs consideration in clinical care and should be addressed in longer, prospective studies.
引用
收藏
相关论文
共 176 条
[1]  
Alexander SPH(2016)Therapeutic potential of cannabis-related drugs Prog Neuro-Pharmacol Biol Psychiatry 64 157-66
[2]  
Aggarwal SK(2009)Medicinal use of cannabis in the Uniter States: historical perspectives, current trends, and future directions J Opioid Manag 5 153-68
[3]  
Carter GT(2013)Endocannabinoids: a unique opportunity to develop multitarget analgesics Pain 154 S87-93
[4]  
Sullivan MD(1990)Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 561-4
[5]  
ZumBrunnen C(1993)Molecular characterization of a peripheral receptor for cannabinoids Nature 365 61-5
[6]  
Morrill R(2014)Systematic review: efficacy and safely of medical marijuana in selected neurologic disorders. Report of the guideline development subcommittee of the American academy of neurology Neurology 82 1556-63
[7]  
Mayer JD(2015)Medical chemistry of cannabinoids Clin Pharmacol Ther 97 553-8
[8]  
Maione S(2015)Cannabinoids for medical use: a systematic review and meta-analysis JAMA 313 2456-73
[9]  
Costa B(2011)Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP) Arthritis Care Res 63 S240-52
[10]  
Vincenzo DM(2015)The cannabinoid use in progressive inflammatory brain disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis Health Technol Assess 19 1-188
12345678910